RxDoctor Payments Data

Sanket Shah, MD

Retina Specialist · Milpitas, CANPI 1528355799

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,436 of the $3,734 with a category attached, or 65.2%. 18 manufacturers reported payments, led by Novartis at 36.8% of the total. Reporting peaked in 2019 at $1,720 and has fallen 81.4% since, to $321 in 2025. That places this record below the midpoint for retina specialist clinicians in CA, where the typical reported total is $3,667.

$3,734in general payments, 2019–2025

Across 44 payments — averaging $84.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • PTC Therapeutics, Inc.$500
  • Bausch & Lomb Americas Inc.$262
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$222
  • Glaukos Corporation$209
  • AbbVie$159
  • plus $1K from 12 others
$62,487in research payments, 2019–2025

Across 3 payments — averaging $20,829 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$62K

What the payments were for

  • Consulting fees$65017%
  • Travel & lodging$64817%
  • Food & beverage$2,43665%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,734 in reported general payments places this provider in the 50th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California

Medicare billing

Part B allowed, 2024
$32,490
Medicare patients
57
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate51$2,426
Latanoprost56$754
Ketorolac Tromethamine20$671
Brimonidine Tartrate44$582
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat31$526
ErythromycinErythromycin Base30$396
Ofloxacin13$197
Timolol Maleate14$105

Paid to pharmacies, not to this prescriber.

Other retina specialist in Milpitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →